Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10

Watanabe, Daisuke; Goshima, Fumi; Mori, Isamu; Tamada, Yasuhiko; Matsumoto, Yoshinari; Nishiyama, Yukihiro

doi:10.1016/j.jdermsci.2007.12.001

Cited by 55 publications

(43 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This has been supported by many studies of oncolytic viruses including HF10. 17,19,[33][34][35] Furthermore, HF10 induces antitumor immunity more efficiently than hrR3, which is also an HSV 1 variant. 17 Oncolytic replication of a virus is an immunogenic event 69 that generates a response against both viral and tumor antigens.…”

Section: X400 X400mentioning

confidence: 99%

“…15 A unique and spontaneously mutated and naturally mutated HSV 1, HF10, has been demonstrated to be an effective oncolytic agent in preclinical contexts including peritoneal dissemination models, breast cancer xenografts and malignant melanoma models. [16][17][18][19] In all these studies, HF10 has been effective in tumor lyses. Previously, we published a promising preliminary clinical study demonstrating the efficacy of HF10 in patients with recurrent breast cancers or unresectable pancreatic carcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

et al. 2011

View full text Add to dashboard Cite

Oncolytic viruses are a promising method of cancer therapy, even for advanced malignancies. HF10, a spontaneously mutated herpes simplex type 1, is a potent oncolytic agent. The interaction of oncolytic herpes viruses with the tumor microenvironment has not been well characterized. We injected HF10 into tumors of patients with recurrent breast carcinoma, and sought to determine its effects on the tumor microenvironment. Six patients with recurrent breast cancer were recruited to the study. Tumors were divided into two groups: saline-injected (control) and HF10-injected (treatment). We investigated several parameters including neovascularization (CD31) and tumor lymphocyte infiltration (CD8, CD4), determined by immunohistochemistry, and apoptosis, determined by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Median apoptotic cell count was lower in the treatment group (P ¼ 0.016). Angiogenesis was significantly higher in treatment group (P ¼ 0.032). Count of CD8-positive lymphocytes infiltrating the tumors was higher in the treatment group (P ¼ 0.008). We were unable to determine CD4-positive lymphocyte infiltration. An effective oncolytic viral agent must replicate efficiently in tumor cells, leading to higher viral counts, in order to aid viral penetration. HF10 seems to meet this criterion; furthermore, it induces potent antitumor immunity. The increase in angiogenesis may be due to either viral replication or the inflammatory response.

show abstract

Section: X400 X400mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…HF10 has been evaluated for therapy in melanoma using an in vitro study that found both murine and human melanoma cells had significant cytolytic effects induced by HF10 infection [50]. An in vivo study used immunocompetent mice with established melanomas that were injected with HF10 either intraperitoneally or intratumorally.…”

Section: Hf10mentioning

confidence: 99%

Oncolytic Virus Immunotherapy for Melanoma

Dharmadhikari

Mehnert

Kaufman

2015

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementMelanoma is a type of skin cancer arising from melanocytes and is increasing in incidence. Although complete surgical excision of early stage lesions may be curative, metastatic melanoma continues to be a major therapeutic challenge. Advances in understanding the molecular pathways that promote tumorigenesis and the interactions between melanoma cells and the immune system have resulted in the approval of several newly targeted agents and immunotherapy strategies for the treatment of advanced disease. Oncolytic virus immunotherapy is a new approach that uses native or attenuated live viruses to selectively kill melanoma cells and induce systemic tumor-specific immune responses. A variety of viruses are now in clinical development with the attenuated oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor, known as talimogene laherparepvec, recently demonstrating an improvement in durable response rate in patients with advanced melanoma compared with granulocyte-macrophage colony stimulating factor alone. A major advantage of talimogene laherparepvec and related agents is the limited toxicity and ability to use each individual tumor as a source of antigen to generate a highly specific antitumor immune response. These agents are easily administered in the out-patient setting and may be a reasonable option for patients with limited metastatic tumor burden, those with a good performance status and without extensive prior treatment, and in those who cannot tolerate more difficult therapeutic regimens. Further investigation into the impact on overall survival as monotherapy and combination of oncolytic virus immunotherapy with other forms of immunotherapy merit high priority for further clinical application of these novel agents for the treatment of melanoma and perhaps other cancers as well.

show abstract

“…HF10 replicates more efficiently with low virulence than wild-type HSV-1. Its safety and effectiveness are tested in many animal models, and it has been used for treatment of breast cancer, malignant melanoma and pancreatic cancer in clinical trial [38][39][40][41]. Recent report showed that HF10 also had effects on the tumor microenvironment in patients with recurrent carcinoma tumor [42].…”

Section: An Overview Of Hsvmentioning

confidence: 99%

Advance in herpes simplex viruses for cancer therapy

Liu

Dai

You

et al. 2013

Sci. China Life Sci.

View full text Add to dashboard Cite

Oncolytic virotherapy is an attractive approach that uses live viruses to selectively kill cancer cells. Oncolytic viruses can be genetically engineered to induce cell lyses through virus replication and cytotoxic protein expression. Herpes simplex virus (HSV) has become one of the most widely clinically used oncolytic agent. Various types of HSV have been studied in basic or clinical research. Combining oncolytic virotherapy with chemotherapy or radiotherapy generally produces synergic action with unclear molecular mechanisms. Arming HSV with therapeutic transgenes is a promising strategy and can be used to complement conventional therapies. As an efficient gene delivery system, HSV has been successfully used to deliver various immunomodulatory molecules. Arming HSV with therapeutic genes merits further investigation for potential clinical application.

show abstract

Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10

Cited by 55 publications

References 44 publications

Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

Oncolytic Virus Immunotherapy for Melanoma

Advance in herpes simplex viruses for cancer therapy

Contact Info

Product

Resources

About